DEPEN

LOE Approaching

penicillamine

NDAORALTABLET
Approved
Nov 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

CLINICAL PHARMACOLOGY Penicillamine is a chelating agent recommended for the removal of excess copper in patients with Wilson's disease. From in vitro studies which indicate that one atom of copper combines with two molecules of penicillamine, it would appear that one gram of penicillamine should…

Pharmacologic Class:

Antirheumatic Agent

Clinical Trials (5)

NCT07215975N/ARecruiting

A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East

Started Feb 2026
200 enrolled
β-thalassemia
NCT07319845Phase 2Not Yet Recruiting

A Study of TAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes

Started Feb 2026
27 enrolled
Myelodysplastic Syndromes
NCT07465029N/AActive Not Recruiting

A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain

Started Feb 2026
1,300 enrolled
Lower-risk Myelodysplastic Syndromes (TD LR-MDS)
NCT07271069N/ARecruiting

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

Started Jan 2026
150 enrolled
Ulcerative Colitis (UC)
NCT07300111Phase 3Not Yet Recruiting

A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)

Started Dec 2025
100 enrolled
Anaemia